Bank of New York Mellon
GPCR icon

Bank of New York Mellon’s Structure Therapeutics GPCR Stock Holding History

Bank of New York Mellon’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,604
Closed -$251K – 4248
2025
Q4 		$251K Buy
+3,604
New +$147K ﹤0.01% 3921

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Bank of New York Mellon's GPCR Position: Q1 2026 in Review

Bank of New York Mellon sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 3,604 shares — an estimated $251K sold.

Bank of New York Mellon first reported a position in GPCR in Q4 2025 and held it in 1 quarter. The position peaked at $251K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Bank of New York Mellon reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of New York Mellon sold 3,604 Structure Therapeutics shares in Q1 2026, an estimated $251K.
  • Bank of New York Mellon first reported a position in Structure Therapeutics in Q4 2025 and held it in 1 quarter.
  • Bank of New York Mellon's Structure Therapeutics position peaked at $251K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Bank of New York Mellon's 13F filing for Q1 2026, filed 5 May 2026.